Citadel Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Citadel Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,800	Closed	-$235K	–	10082
2019 Q2	$235K	Buy	+7,800	New	+$179K	﹤0.01%	7958

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Citadel Advisors's RARX Position: Q2 2020 in Review

Citadel Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 42,956 shares — an estimated $2.06M sold.

Citadel Advisors first reported a position in RARX in Q3 2017 and held it in 10 quarters. The position peaked at $37.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Citadel Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Citadel Advisors sold 42,956 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.06M.
Citadel Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
Citadel Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $37.2M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.